Skip to Content

WPI 2233 (Tamoxifen Citrate 20 mg)

Pill with imprint WPI 2233 is White, Round and has been identified as Tamoxifen Citrate 20 mg. It is supplied by Watson Pharmaceuticals, Inc..

Tamoxifen is used in the treatment of breast cancer, adjuvant; breast cancer, metastatic; breast cancer; breast cancer, male; breast cancer, palliative and belongs to the drug classes hormones/antineoplastics, selective estrogen receptor modulators. There is positive evidence of human fetal risk during pregnancy. Tamoxifen 20 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 2233

Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233 Front
Tamoxifen citrate 20 mg WPI 2233 Back
Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233

Tamoxifen Citrate

Imprint
WPI 2233
Strength
20 mg
Color
White
Size
10.00 mm
Shape
Round
Availability
Prescription only
Drug Class
Hormones/antineoplastics, Selective estrogen receptor modulators
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
Watson Pharmaceuticals, Inc.
National Drug Code (NDC)
00591-2233
Inactive Ingredients
croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized corn starch

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.